![]()
|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J Biol Chem, Vol. 275, Issue 16, 11541-11544, April 21, 2000
-Synthase Is a Pyridoxal Phosphate Enzyme
but, Unlike the Human Enzyme, Is Not a Heme Protein*
From the Laboratory of Biochemistry and Genetics, NIDDK, National Institutes of Health, Bethesda, Maryland 20892-0830
| |
ABSTRACT |
|---|
|
|
|---|
Our studies of cystathionine Elevated plasma homocysteine is an important risk factor in
coronary heart disease and other human diseases (1-3). One of the two
major routes for detoxication of homocysteine is the pyridoxal phosphate
(PLP)1-dependent
-synthase from
Saccharomyces cerevisiae (yeast) are aimed at (1)
clarifying the cofactor dependence and catalytic mechanism and (2)
obtaining a system for future investigations of the effects of
mutations that cause human disease (homocystinuria or coronary heart
disease). We report methods that yielded high expression of the yeast
gene in Escherichia coli and of purified yeast
cystathionine
-synthase. The absorption and circular dichroism
spectra of the homogeneous enzyme were characteristic of a pyridoxal
phosphate enzyme and showed the absence of heme, which is found in
human and rat cystathionine
-synthase. The absence of heme in the
yeast enzyme facilitates spectroscopic studies to probe the catalytic
mechanism. The reaction of the enzyme with L-serine in the
absence of L-homocysteine produced the aldimine of
aminoacrylate, which absorbed at 460 nm and had a strong negative
circular dichroism band at 460 nm. The formation of this intermediate
from the product, L-cystathionine, demonstrates the partial
reversibility of the reaction. Our results establish the overall
catalytic mechanism of yeast cystathionine
-synthase and provide a
useful system for future studies of structure and function. The absence
of heme in the functional yeast enzyme suggests that heme does not play
an essential catalytic role in the rat and human enzymes. The results
are consistent with the absence of heme in the closely related enzymes
O-acetylserine sulfhydrylase, threonine deaminase, and
tryptophan synthase.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-replacement reaction with L-serine catalyzed by
cystathionine
-synthase (CBS; EC 4.2.1.22).
The deduced sequences of human (4,5), rat (6), and
Saccharomyces cerevisiae (yeast) (7,8) CBS are similar. The
finding that human CBS complements the cysteine auxotrophy of a yeast strain lacking CBS (5) demonstrates the functional conservation of the
human and yeast genes.
(Eq. 1)
The remarkable observation that the sequence of rat CBS (6) is
identical to the sequence of rat hemoprotein H-450 (9) led to the
discovery that rat and human CBS contain both PLP and heme (10). Heme
may play a role in redox regulation of the human enzyme and in binding
homocysteine (11,12). Although yeast CBS has been purified to
homogeneity (13), the absorption spectrum and cofactor content have not
been reported.2 Here, we
demonstrate that purified yeast CBS contains PLP but not heme. Because
the absence of heme facilitates spectroscopic studies of the PLP and of
enzyme-substrate intermediates, we are able to demonstrate directly
that CBS converts L-serine to an aminoacrylate
intermediate, as expected for a PLP enzyme that catalyzes a
-replacement reaction (14,15).
| |
EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Chemicals--
L-Cystathionine and
L-serine were from Fluka.
-Aminolevulinic acid,
L-homocysteine thiolactone, aprotinin, pepstatin A,
leupeptin, benzamidine hydrochloride, TPCK, TLCK, and PMSF were from
Sigma. Gigapite was from Seikagaku, Japan. L-Homocysteine
was prepared from L-homocysteine thiolactone as described
(16, 17). L-[U-14C]Serine (160 mCi/mmol) was
from NEN Life Science Products.
Construction of pSEC, a Vector for Overexpression of CBS-- To overexpress CBS from S. cerevisiae, we ligated the 1.5-kb PCR product containing the CBS gene from PSTR4-2 (cys4)3 (18) and the restricted pTRC 99A vector (Amersham Pharmacia Biotech) to yield the expression vector pSEC (Fig. 1). The PCR product of CBS was designed using an upstream PCR primer (5'-pATGACTAAATCTGAGCAGCAGCAAGCC-3'), which starts the 5'-phosphorylated ATG, and a downstream PCR primer (5'-GTTTGCTTTTATCTGCAGCGTGGG-3'), which extends from 8 to 31 bases after the termination codon for the CBS open reading frame. The boldface bases are changes that introduce a PstI restriction site. PCR reactions were carried out in 50 µl with 2-min denaturation at 94 °C followed by 35 cycles of 1-min denaturation at 94 °C, 30-s annealing at 50 °C, and 1-min extension at 72 °C using Pfu DNA polymerase and the reaction conditions described in the Stratagene catalog. The ethanol-precipitated PCR products were solubilized with TE buffer, pH 8.0 (10 mM Tris-HCl containing 1 mM EDTA), restricted by PstI (Amersham Pharmacia Biotech), and isolated by 0.7% agarose (Life Technologies, Inc., Ultra Pure) gel electrophoresis. The putative 1.5 kb CBS gene was cut out of the gel and extracted using a Geneclean II kit (Bio 101, Inc.).
The overexpression vector pTrc 99A was restricted by NcoI,
mung-bean nuclease (19), and then by PstI. After each
restriction step, the 4.2-kb product was purified by agarose gel
electrophoresis and extraction as described above. The restricted pTrc
99A vector was ligated with the amplified CBS PCR product using T4 DNA
ligase and transformed into host E. coli DH5
(Life
Technologies, Inc.). The seven-base distance between the AGGA site
(E. coli ribosome binding site) of pTrc99A and the CBS start
codon gives a high yield of overexpression. Recombinant pSEC was
isolated using a QIA plasmid kit (Qiagen), and the total DNA sequence
of the 1.5-kb insert was confirmed by DNA sequence analysis (Biopolymer
Core Facility, University of Maryland at Baltimore). Finally, pSEC was
transformed into E. coli XL1-blue (Stratagene) for overexpression.
Determination of CBS Activity and Protein Concentration-- Protein concentrations were determined by the Coomassie Blue protein assay reagent (Pierce) using bovine serum albumin as a standard or from the specific absorbance of purified CBS at 280 nm (A280 0.1% = 0.94).4 CBS activity was determined by a modification of a standard method (20). The reaction mixture, which contained 200 mM Tris-HCl, pH 8.6, 20 µM PLP, 0.25 mg/ml bovine serum albumin, 5 mM L-[U-14C]serine (800 cpm/nmol), and CBS (0.02-0.1 µg) in 18 µl, was preincubated for 5 min at 37 °C. The reaction was initiated by adding 2 µl of 50 mM homocysteine to 5 mM and was terminated after 10-15 min by adding 5 µl of 50% trichloroacetic acid. After the mixture was centrifuged for 3 min, 5 µl of the supernatant was applied to a cellulose thin layer chromatography plate (Kodak). The product, L-[14C]cystathionine, was separated from L-[14C]serine by ascending thin layer chromatography in 2-propanol/formic acid/H20 (80/6/20 v/v). Radioactivity of the product was determined by PhosphorImager (Molecular Dynamics). One unit of activity is defined as the production of 1 µmol of L-cystathionine/h at 37 °C.
Overexpression and Purification of CBS--
A 1-liter culture of
E. coli XL1-blue transformed with pSEC was grown at 37 °C
in Super Broth (BioWhittaker or KD Medical) containing tryptone (12 g/liter), yeast extract (24 g/liter), glycerol (6.3 g/liter),
K2HPO4 (12.5 g/liter),
KH2PO4 (3.8 g/liter),
-aminolevulinic acid
(50 mg/liter), ampicillin (100 mg/liter), and 20 ml of 50-fold
concentrated Vogel and Bonner minimal medium (21). A 10% inoculum was
added to the medium, and growth proceeded for ~3-4 h until the
OD650 reached 2.5. IPTG was added to 0.1 mM,
and growth was continued at 30 °C for 14-18 h. We found that adding
IPTG to cells at high density (OD650 = 2.5) gave a higher yield of enzyme than adding IPTG to cells at lower density. Growth in
triple-indented Tunair flasks with loose fitting plastic caps (Shelton
Scientific Manufacturing, Inc.) (22) gave the highest yield of cells.
Cells were harvested by centrifugation, washed with 0.85% NaCl
containing 1 mM dithiothreitol, resuspended in Buffer BP
(50 mM sodium/bicine, pH 7.8, containing 10 mM
EDTA, 10 mM
-mercaptoethanol, 0.1 mM PLP, 1 mM PMSF, 0.1 mM TLCK, 0.1 mM TPCK,
1 mg/liter aprotinin, 2 mg/liter leupeptin, 2 mg/liter pepstatin, and 1 mM benzamidine-HCl), and disrupted by passaging twice
through a French press at 8,000 p.s.i. The suspension was centrifuged
at 12,000 × g for 30 min. The supernatant (crude
extract) had a specific activity of 253 units/mg.
Eight ml of a 2% solution of protamine sulfate in Buffer BP was added
dropwise to the 50-ml crude extract with stirring at room temperature
followed by additional stirring for 20 min. The suspension was
centrifuged, and the precipitate was discarded. The supernatant
solution was fractionated with ammonium sulfate at pH 7.5. The 30-60%
ammonium sulfate fraction was dialyzed against three changes of Buffer
BP at 4 °C for 6 h. The dialyzed enzyme solution (42 ml) was
loaded onto a 2.5 × 20-cm column of DEAE-Sephacel, which was then
washed with 300 ml of Buffer BP. The enzyme was eluted with a 1-liter
linear gradient from 0 to 0.5 M NaCl in Buffer BP.
Fractions were analyzed by SDS-polyacrylamide gel electrophoresis and
by activity assay. The active fractions, which eluted between 0.18-0.25 M NaCl, were pooled, concentrated, and dialyzed
against Buffer KP (10 mM potassium phosphate, pH 7.8, containing 10 mM EDTA, 10 mM
-mercaptoethanol, 0.1 mM PLP, 1 mM PMSF, 0.1 mM TLCK, 0.1 mM TPCK, 1 ml/liter aprotinin, 2 mg/liter leupeptin, 2 mg/liter pepstatin, and 1 mM
benzamidine-HCl at pH 7.8). The dialyzed DEAE fractions had a specific
activity of 438 units/mg (yield = 64%).
The dialyzed enzyme solution (40 ml) was applied to a Gigapite column
(3.1 × 27 cm) equilibrated with Buffer KP. Gigapite is a modified
form of hydroxyapatite that has large particles and gives a high flow
rate. The column was washed with 400 ml of Buffer KP followed by 300 ml
of Buffer KP that contained 50 mM potassium phosphate. The
enzyme was eluted with a 1.8-liter linear gradient ranging from 50 to
400 mM potassium phosphate in Buffer KP. The active
fractions, which eluted at 150-200 mM potassium phosphate,
were concentrated to 10-30 mg/ml, dialyzed against Buffer K (50 mM potassium phosphate, pH 7.5, containing 1 mM
EDTA, 1 mM dithiothreitol, and 0.02 mM PLP),
and stored at
85 °C. The Gigapite fractions had a specific
activity of 470 units/mg (yield = 49%) and were >95% pure by
the criterion of SDS-polyacrylamide gel electrophoresis. Approximately
600 mg of homogenous CBS was obtained from a 1-liter culture. All
procedures were completed within 72 h to limit proteolysis.
Spectroscopic Methods--
Absorption spectra of CBS were made
using a Hewlett Packard 8452-diode array spectrophotometer
thermostatted at 25 °C by a Peltier junction temperature-controlled
cuvette holder. CD measurements (mean residue ellipticity in degree
cm2/dmol) were made at 25 °C in a Jasco J-715
spectrophotometer interfaced with a personal computer (Japan
Spectroscopic Co., Easton, MD).
| |
RESULTS AND DISCUSSION |
|---|
|
|
|---|
Our new expression vector, pSEC (Fig.
1), gave a very high level of expression
of the yeast CBS gene in E. coli (see "Experimental Procedures"). A 2-fold purification of yeast CBS by DEAE-Sephacel and
Gigapite chromatography yielded homogeneous CBS in approximately 50%
yield. Although yeast CBS has been purified previously (13), the
absorption spectrum was not reported.2 The absorption
spectrum of our purified yeast CBS (Fig.
2A) exhibited major peaks at
280 and 412 nm in a ratio of 1: 0.16, typical of a PLP enzyme (15).
Removal of the PLP resulted in an apoenzyme having no absorbance in the
visible range.4
|
|
In contrast, the absorption spectra of rat and human CBS (10-12,
23-26) exhibit a visible absorption band at 428 nm, which is approximately equal in intensity to the 280 nm absorption band. The 428 nm band in rat and human CBS is attributed to the presence of both heme
and PLP, which have overlapping visible absorption spectra in the
410-430 nm region. The absence of heme in yeast CBS is not due to
expression in E. coli; human CBS expressed in E. coli does contain heme. We added
-aminolevulinate to the
E. coli growth medium because the presence of this precursor
of heme has been shown to increase the heme content of human CBS
(27).
The presence of heme in rat and human CBS is surprising because no
other PLP enzyme has been reported to contain heme. Several PLP enzymes
that catalyze
-elimination and
-replacement reactions exhibit a
sequence similarity to rat, human, and yeast CBS (28). Three of these
related enzymes, O-acetylserine sulfhydrylase (29), the
-subunit of tryptophan synthase (30), and threonine deaminase (31),
have been analyzed by x-ray crystallography and shown to exhibit
structural similarity.
The spectroscopic properties of PLP provide a sensitive probe for
detecting chemical intermediates in PLP-dependent
-replacement reactions (Scheme 1) (15)
and in other PLP-dependent reactions. The absence of heme
in yeast CBS facilitates spectroscopic studies to detect intermediates
in the reactions of CBS and to probe the reaction mechanism. The
addition of L-serine to yeast CBS resulted in the
disappearance of the 412 nm band attributed to the internal aldimine
(E in Scheme 1) and the appearance of a new spectroscopic species with a major band centered at 460 nm and a shoulder at 330 nm
(Fig. 2A). The 460 nm band is likely due to the aldimine of
aminoacrylate (E-AA in Scheme 1), which has been detected in the reaction of O-acetylserine sulfhydrylase with
O-acetyl-L-serine (32-34) and of
D-serine dehydratase with D-serine (35). The
330 nm shoulder may be due to a different tautomer of E-AA, which is
the predominant intermediate in the reaction of the closely related
tryptophan synthase with L-serine (36). Our results (Fig.
2A) demonstrate the E-AA intermediate by direct absorption spectroscopy for the first time. Previous studies of the reaction of
truncated or full-length human CBS with L-serine detected a putative aminoacrylate intermediate by difference absorption
spectroscopy (12) or by fluorescence spectroscopy (fluorescence
emission at ~400 nm with excitation at 330 nm) (11). Rapid scanning
spectroscopy may be needed to detect the external aldimine intermediate
(E-Ser in Scheme 1) in the reaction of CBS with
L-serine or intermediates in the reaction of CBS with
L-serine and L-homocysteine. The addition of
L-homocysteine to CBS in the presence of
L-serine under the conditions shown in Fig. 2A
resulted in a transient decrease in absorbance at 460 nm (data not
shown), providing additional evidence that the 460 nm band is due to
the E-AA intermediate. The reaction of the substrate analog
L-alanine with yeast CBS yielded a band at 420 nm, which is
a wavelength characteristic of the expected external aldimine, E-Ala
(15). E-Ala is analogous to E-Ser in Scheme 1.
|
Yeast CBS exhibited a positive CD band centered in the visible absorption band of the cofactor at 412 nm (Fig. 1B), as reported for O-acetylserine sulfhydrylase (37) and tryptophan synthase (38, 39). The addition of L-serine gave a negative CD band centered at 460 nm and a strong positive band at 280 nm. Negative visible CD bands for E-AA have been reported for O-acetylserine sulfhydrylase (37) and tryptophan synthase (39, 40). The tryptophan synthase E-AA intermediate also has a strong positive band at 280 nm (40). The addition of L-alanine gave a negative CD band centered at 430 nm.
To probe the reversibility of the postulated CBS reaction in Scheme I,
we measured the absorption spectra (Fig.
3A) and CD spectra (Fig.
3B) of yeast CBS in the presence of
L-cystathionine. The initial (15 s) absorption spectrum
showed a peak at 430 nm and a prominent shoulder at 460 nm. The
absorbance at 460 nm decreased with time (inset, Fig.
3A). The CD spectrum (~6 min) exhibited a negative band at
460 nm and positive bands at 400 and 280 nm. Thus,
L-cystathionine appears to undergo the reverse reaction to
form E-AA and an aldimine, either the internal aldimine, E, or an
external aldimine, E-Ser or E-Cyst (Scheme 1).
|
Our results provide the first direct, spectroscopic evidence that
the reaction catalyzed by yeast CBS proceeds through the postulated
intermediates in Scheme I and that the reaction is at least partially
reversible. The absorption spectrum in Fig. 2A showed that
L-serine was largely or completely converted to E-AA in the
absence of L-homocysteine. This result demonstrates that
the CBS reaction does not proceed by direct displacement of the OH of
L-serine, as proposed by Braunstein and Goryachenkova (41).
Our results, therefore, resolve an old controversy over the mechanism
of CBS (14, 15, 41) and are consistent with the stereochemical data
showing that displacement of the OH of L-serine proceeds
with retention of configuration (14). The direct displacement mechanism
of Braunstein and Goryachenkova (41) was proposed to explain the
inability of CBS to catalyze the conversion of L-serine to
pyruvate and NH3 by a
-elimination reaction. Our data
provide evidence that CBS, like the tryptophan synthase
2
2 complex and O-acetylserine
sulfhydrylase, forms a stable, enzyme-bound E-AA intermediate that does
not undergo hydrolysis or further reaction in the absence of an
added nucleophile.
In conclusion, we have demonstrated that yeast CBS is a
heme-independent, PLP enzyme and have carried out initial spectroscopic studies that establish the overall catalytic mechanism. Work is in
progress to investigate the reaction kinetics, domain composition, oligomeric structure, and substrate and nucleophile specificity of
yeast CBS.4 The absence of heme in the functional yeast
enzyme shows that heme is not essential for catalysis and suggests that
heme does not play an essential catalytic role in the rat and human
enzymes. The results are consistent with the absence of heme in the
closely related enzymes O-acetylserine sulfhydrylase,
threonine deaminase, and tryptophan synthase.
| |
FOOTNOTES |
|---|
* A preliminary report of portions of this work was presented at the 10th International Symposium of Vitamin B6 and Carbonyl Catalysis and 4th Meeting on PQQ and Quinoproteins, Santa Fe, New Mexico, October 31-November 5, 1999.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Laboratory of
Biochemistry and Genetics, NIDDK, National Institutes of Health, Bldg.
8, Rm. 225, MSC 0830, 8 Center Dr., Bethesda, MD 20892-0830. Tel.:
301-496-2763; Fax: 301-402-0240; E-mail: EdithM@intra.niddk.nih. gov.
2 After this work was completed and reported in abstract and poster form at the 10th International Symposium of Vitamin B6 and Carbonyl Catalysis and 4th Meeting on PQQ and Quinoproteins, Santa Fe, New Mexico, October 31-November 5, 1999, we learned that another group had purified CBS from S. cerevisiae and found that the enzyme is not dependent on heme (K. N. Maclean, M. Janosik, J. Oliveriusova, V. Kery, and J. P. Kraus, submitted for publication).
3 PSTR4-2 (cys4) was a generous gift from Dr. Yolande Surdin- Kerjan.
4 K.-H. Jhee, P. McPhie, and E. W. Miles, manuscript in preparation.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
PLP, pyridoxal
phosphate;
CBS, cystathionine
-synthase;
IPTG, isopropyl
thioglucoside;
PMSF, phenylmethylsulfonyl fluoride;
TLCK, N-
-p-tosyl-L-lysine chloromethyl ketone;
TPCK, N-tosyl-L-phenylalanine chloromethyl
ketone;
PCR, polymerase chain reaction;
kb, kilobase pair(s).
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Mudd, S. H., Levy, H. L., and Skovby, F. (1995) in The Metabolic Basis of Inherited Disease (Scriver, C. R. , Beaudet, A. L. , Sly, W. S. , and Valle, D., eds), 6th Ed. , pp. 1272-1327, McGraw-Hill, New York |
| 2. | Chen, P., Poddar, R., Tipa, E. V., Dibello, P. M., Moravec, C. D., Robinson, K., Green, R., Kruger, W. D., Garrow, T. A., and Jacobsen, D. W. (1999) Adv. Enzyme Regul. 39, 93-109 |
| 3. | Taylor, L. M., Jr., Moneta, G. L., Sexton, G. J., Schuff, R. A., and Porter, J. M. (1999) J. Vasc. Surg. 29, 8-21 |
| 4. | Kraus, J. P., Le, K., Swaroop, M., Ohura, T., Tahara, T., Rosenberg, L. E., Roper, M. D., and Kozich, V. (1993) Hum. Mol. Genet. 2, 1633-1638 |
| 5. | Kruger, W. D., and Cox, D. R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 6614-6618 |
| 6. | Swaroop, M., Bradley, K., Ohura, T., Tahara, T., Roper, M. D., Rosenberg, L. E., and Kraus, J. P. (1992) J. Biol. Chem. 267, 11455-11461 |
| 7. | Ono, B., Heike, C., Yano, Y., Inoue, T., Naito, K., Nakagami, S., and Yamane, A. (1992) Curr. Genet. 21, 285-289 |
| 8. | Cherest, H., and Surdin-Kerjan, Y. (1992) Genetics 130, 51-58 |
| 9. | Ishihara, S., Morohashi, K., Sadano, H., Kawabata, S., Gotoh, O., and Omura, T. (1990) J. Biochem. (Tokyo) 108, 899-902 |
| 10. | Kery, V., Bukovska, G., and Kraus, J. P. (1994) J. Biol. Chem. 269, 25283-25288 |
| 11. | Taoka, S., West, M., and Banerjee, R. (1999) Biochemistry 38, 2738-2744 |
| 12. | Kery, V., Poneleit, L., Meyer, J. D., Manning, M. C., and Kraus, J. P. (1999) Biochemistry 38, 2716-2724 |
| 13. | Ono, B., Kijima, K., Inoue, T., Miyoshi, S., Matsuda, A., and Shinoda, S. (1994) Yeast 10, 333-339 |
| 14. | Borcsok, E., and Abeles, R. H. (1982) Arch. Biochem. Biophys. 213, 695-707 |
| 15. | Miles, E. W. (1986) in Pyridoxal Phosphate: Chemical, Biochemical and Medical Aspects (Dolphin, D., Poulson, D., and Avramovic, O., eds) Part B, Vol. 1, pp. 253-310, John Wiley and Sons, New York |
| 16. | Suda, M., Nakagawa, H., and Kimura, H. (1973) in Methods in Enzymology (Tabor, H. , and Tabor, C. W., eds), Vol. 17B , pp. 454-458, Academic Press, New York |
| 17. | Drummond, J. T., Jarrett, J., Gonzalez, J. C., Huang, S., and Matthews, R. G. (1995) Anal. Biochem. 228, 323-329 |
| 18. | Cherest, H., Thomas, D., and Surdin-Kerjan, Y. (1993) J. Bacteriol. 175, 5366-5374 |
| 19. | Hasan, N., Kim, S. C., Podhajska, A. J., and Szybalski, W. (1986) Gene 50, 55-62 |
| 20. | Kraus, J., Packman, S., Fowler, B., and Rosenberg, L. E. (1978) J. Biol. Chem. 253, 6523-6528 |
| 21. | Vogel, H. J., and Bonner, D. M. (1956) J. Biol. Chem. 218, 97-106 |
| 22. | Tunac, J. B. (1989) J. Ferment. Bioeng. 68, 157-159 |
| 23. | Bukovska, G., Kery, V., and Kraus, J. P. (1994) Protein Expression Purif. 5, 442-448 |
| 24. | Kery, V., Poneleit, L., and Kraus, J. P. (1998) Arch. Biochem. Biophys. 355, 222-232 |
| 25. | Taoka, S., Ohja, S., Shan, X., Kruger, W. D., and Banerjee, R. (1998) J. Biol. Chem. 273, 25179-25184 |
| 26. | Taoka, S., Widjaja, L., and Banerjee, R. (1999) Biochemistry 38, 13155-13161 |
| 27. | Kery, V., Elleder, D., and Kraus, J. P. (1995) Arch. Biochem. Biophys. 316, 24-29 |
| 28. | Grishin, N. V., Phillips, M. A., and Goldsmith, E. J. (1995) Protein Sci. 4, 1291-1304 |
| 29. | Burkhard, P., Rao, G. S. J., Hohenester, E., Schnackerz, K. D., Cook, P. F., and Jansonius, J. N. (1998) J. Mol. Biol. 283, 121-133 |
| 30. | Hyde, C. C., Ahmed, S. A., Padlan, E. A., Miles, E. W., and Davies, D. R. (1988) J. Biol. Chem. 263, 17857-17871 |
| 31. | Gallagher, D. T., Gilliland, G. L., Xiao, G., Zondlo, J., Fisher, K. E., Chinchilla, D., and Eisenstein, E. (1998) Structure 6, 465-475 |
| 32. | Cook, P. F., and Wedding, R. T. (1976) J. Biol. Chem. 251, 2023-2029 |
| 33. | Cook, P. F., Hara, S., Nalabolu, S., and Schnackerz, K. D. (1992) Biochemistry 31, 2298-2303 |
| 34. | Woehl, E. U., Tai, C. H., Dunn, M. F., and Cook, P. F. (1996) Biochemistry 35, 4776-4783 |
| 35. | Schnackerz, K. D., Ehrlich, J. H., Giesemann, W., and Reed, T. A. (1979) Biochemistry 18, 3557-3563 |
| 36. | Drewe, W. J., and Dunn, M. F. (1985) Biochemistry 24, 3977-3987 |
| 37. | Schnackerz, K. D., Tai, C. H., Simmons, J. W., 3rd, Jacobson, T. M., Rao, G. S., and Cook, P. F. (1995) Biochemistry 34, 12152-12160 |
| 38. | Miles, E. W., and Moriguchi, M. (1977) J. Biol. Chem. 252, 6594-6599 |
| 39. | Lane, A. N., and Kirschner, K. (1983) Eur. J. Biochem. 129, 571-582 |
| 40. | Kayastha, A. M., Sawa, Y., Nagata, S., and Miles, E. W. (1991) J. Biol. Chem. 266, 7618-7625 |
| 41. | Braunstein, A. E., and Goryachenkova, E. V. (1984) Adv. Enzymol. 56, 1-89 |
This article has been cited by other articles:
![]() |
J. Oliveriusova, V. Kery, K. N. Maclean, and J. P. Kraus Deletion Mutagenesis of Human Cystathionine beta -Synthase. IMPACT ON ACTIVITY, OLIGOMERIC STATUS, AND S-ADENOSYLMETHIONINE REGULATION J. Biol. Chem., December 6, 2002; 277(50): 48386 - 48394. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Taoka and R. Banerjee Stopped-flow Kinetic Analysis of the Reaction Catalyzed by the Full-length Yeast Cystathionine beta -Synthase J. Biol. Chem., June 14, 2002; 277(25): 22421 - 22425. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. C. Lo, L. Hamer, and J. E. Hamer Molecular Characterization of a Cystathionine Beta-Synthase Gene, CBS1, in Magnaporthegrisea Eukaryot. Cell, April 1, 2002; 1(2): 311 - 314. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Shan, R. L. Dunbrack Jr, S. A. Christopher, and W. D. Kruger Mutations in the regulatory domain of cystathionine {beta}-synthase can functionally suppress patient-derived mutations in cis Hum. Mol. Genet., March 1, 2001; 10(6): 635 - 643. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bruno, F. Schiaretti, P. Burkhard, J. P. Kraus, M. Janosik, and A. Mozzarelli Functional Properties of the Active Core of Human Cystathionine beta -Synthase Crystals J. Biol. Chem., January 5, 2001; 276(1): 16 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nozaki, Y. Shigeta, Y. Saito-Nakano, M. Imada, and W. D. Kruger Characterization of Transsulfuration and Cysteine Biosynthetic Pathways in the Protozoan Hemoflagellate, Trypanosoma cruzi. ISOLATION AND MOLECULAR CHARACTERIZATION OF CYSTATHIONINE beta -SYNTHASE AND SERINE ACETYLTRANSFERASE FROM TRYPANOSOMA J. Biol. Chem., February 23, 2001; 276(9): 6516 - 6523. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Kabil, S. Toaka, R. LoBrutto, R. Shoemaker, and R. Banerjee Pyridoxal Phosphate Binding Sites Are Similar in Human Heme-dependent and Yeast Heme-independent Cystathionine beta -Synthases. EVIDENCE FROM 31P NMR AND PULSED EPR SPECTROSCOPY THAT HEME AND PLP COFACTORS ARE NOT PROXIMAL IN THE HUMAN ENZYME J. Biol. Chem., May 25, 2001; 276(22): 19350 - 19355. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |